Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4704—2-Quinolinones, e.g. carbostyril
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

• MS Multiple Sclerosis
• MS disease stages and/or types are described in Multiple Sclerosis Therapeutics (Duntiz, 1999 ) .
• RRMS relapsing- remitting multiple sclerosis
• SPMS secondary progressive MS
• PPMS Primary progressive MS
• PPMS and SPMS are thought to be dominated by axonal degeneration in the absence of overt inflammation which is most likely a result of oxidative damage and/or increased susceptibility to injury caused by the loss of the myelin sheath (Spain 200 9 ) .
• PRMS Progressive- relapsing MS
• PRMS patients experience disease progression from the very beginning — but they experience occasional relapses (also called attacks or exacerbations) as well. Because PRMS is progressive from onset, the doctor may initially diagnose it as PPMS, subsequently changing the diagnosis to PRMS when a relapse occurs (National Multiple Sclerosis Society Website) .
• Laquinimod is a novel synthetic compound with high oral bioavailability which has been suggested as an oral formulation for the treatment of Multiple Sclerosis (MS) (Polman, 2005; Sandberg-Wollheim, 2005) .
• MS Multiple Sclerosis
• Laquinimod and its sodium salt form are described, for example, in U.S. Patent No. 6,077,851.
• Laquinimod showed a favorable safety and tolerability profile in two phase III trials for treating relapsing-remitting multiple sclerosis patients (Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment; Teva Pharma, Active Biotech Post Positive Laquinimod Phase 3 ALLEGRO Results) .
• This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject.
• This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis .
• This invention also provides laquinimod for use in the manufacture of a medicament for treating a subject afflicted a progressive form of multiple sclerosis.
• This invention also provides a pharmaceutical composition comprising an effective amount of laquinimod for treating a progressive form of multiple sclerosis.
• This invention also provides a pharmaceutical composition in unit dosage form, useful in treating a subject afflicted with a progressive form of multiple sclerosis, which comprises an amount of laquinimod; which amount of said laquinimod in said composition is effective, upon administration to said subject of one or more of said unit dosage forms of said composition, to treat the subject.
• This invention also provides a package comprising: a) a pharmaceutical composition comprising an amount of laquinimod; and b) instruction for use of the pharmaceutical composition to treat a subject afflicted with a progressive form of multiple sclerosis .
• This invention also provides a therapeutic package for dispensing to, or for use in dispensing to, a subject afflicted with a progressive form of multiple sclerosis, which comprises: a) one or more unit doses, each such unit dose comprising an amount of laquinimod thereof, wherein the amount of said laquinimod in said unit dose is effective, upon administration to said subject, to treat the subject, and b) a finished pharmaceutical container therefor, said container containing said unit dose or unit doses, said container further containing or comprising labeling directing the use of said package in the treatment of said subj ect .
• Figure 1 shows disability progression of various forms of multiple sclerosis with time.
• This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject.
• the progressive form of multiple sclerosis is Primary Progressive Multiple Sclerosis (PPMS) .
• the progressive form of multiple sclerosis is Progressive Remitting Multiple Sclerosis (PRMS) .
• the progressive form of multiple sclerosis is Secondary Progressive Multiple Sclerosis (SPMS) .
• the human subject is afflicted with a progressive form of multiple sclerosis other than a relapsing form of multiple sclerosis.
• the subject has an Expanded Disability Status Scale (EDSS) score of 3.0-6.5 at baseline. In another embodiment, the subject has an Expanded Disability Status Scale (EDSS) score of greater than 5.5 at baseline. In yet another embodiment, the subject has a Pyramidal Functional Systems (FS) score of ⁇ 2 at baseline .
• EDSS Expanded Disability Status Scale
• FS Pyramidal Functional Systems
• the progressive form of multiple sclerosis is Secondary Progressive Multiple Sclerosis (SPMS) and the subject has an Expanded Disability Status Scale (EDSS) score of greater than 5.5 at baseline.
• the progressive form of multiple sclerosis is Primary Progressive Multiple Sclerosis
• the amount of laquinimod is effective to inhibit progression of a symptom of the progressive form of multiple sclerosis in the subject. In another embodiment, the amount of laquinimod is effective to reduce a symptom of the progressive form of multiple sclerosis in the subject.
• the symptom is brain atrophy. In another embodiment, brain atrophy is measured by the change in brain volume from baseline.
• the symptom is impaired cognitive function.
• cognitive function is measured by the subject's Brief International Cognitive Assessment for MS (BICAMS) score.
• the symptom is the subject's disability. In another embodiment, the subject's disability is measured by the Expanded Disability Status Scale (EDSS) score.
• EDSS Expanded Disability Status Scale
• laquinimod is administered via oral administration. In another embodiment, laquinimod is administered daily. In another embodiment, laquinimod is administered more often than once daily. In yet another embodiment, laquinimod is administered less often than once daily.
• the amount laquinimod administered is 0.5-6.0 mg/day. In another embodiment, the amount laquinimod administered is 0.1-2.5 mg/day. In another embodiment, the amount laquinimod administered is 0.25-2.0 mg/day. In another embodiment, the amount laquinimod administered is 0.3-0.9 mg/day.
• the amount laquinimod administered is 0.5- 1.2 mg/day. In yet another embodiment, the amount laquinimod administered is 0.6-1.8 mg/day.
• the amount laquinimod administered is 0.25 mg/day. In another embodiment, the amount laquinimod administered is 0.3 mg/day. In another embodiment, the amount laquinimod administered is 0.5 mg/day. In another embodiment, the amount laquinimod administered is 0.6 mg/day. In another embodiment, the amount laquinimod administered is 0.9 mg/day. In another embodiment, the amount laquinimod administered is 1.0 mg/day. In another embodiment, the amount laquinimod administered is 1.2 mg/day. In another embodiment, the amount laquinimod administered is 1.5 mg/day. In another embodiment, the amount laquinimod administered is 1.8 mg/day. In another embodiment, the amount laquinimod administered is 2.0 mg/day. In another embodiment, the amount laquinimod administered is 2.5 mg/day. In yet another embodiment, the amount of laquinimod administered is about the amounts disclosed above.
• the periodic administration continues for at least 1 week. In another embodiment, the periodic administration continues for at least 2 weeks. In another embodiment, the periodic administration continues for at least 3 weeks. In another embodiment, the periodic administration continues for at least 4 weeks. In another embodiment, the periodic administration continues for at least 5 weeks. In another embodiment, the periodic administration continues for at least 6 weeks. In another embodiment, the periodic administration continues for at least 12 weeks. In another embodiment, the periodic administration continues for at least 24 weeks. In another embodiment, the periodic administration continues for at least 3 months. In another embodiment, the periodic administration continues for at least 6 months. In yet another embodiment, the periodic administration continues for at least 15 months.
• laquinimod is laquinimod sodium.
• the subject is a naive human patient to laquinimod.
• the subject is a naive human patient to a multiple sclerosis therapy.
• the subject is a naive human patient to any multiple sclerosis therapy.
• This invention also provides laquinimod for use in treating a human subject afflicted with a progressive form of multiple sclerosis .
• This invention also provides laquinimod for use in the manufacture of a medicament for treating a subject afflicted a progressive form of multiple sclerosis.
• This invention also provides a pharmaceutical composition compri sing an effective amount of laquinimod for treating a progressive form of multiple sclerosis.
• This invention also provides a pharmaceutical composition in unit dosage form, useful in treating a subject afflicted with a progressive form of multiple sclerosis, which comprises an amount of laquinimod; which amount of said laquinimod in said composition is effective, upon administration to said subject of one or more of said unit dosage forms of said composition, to treat the subject.
• This invention also provides a package comprising: a) a pharmaceutical composition comprising an amount of laquinimod; and b) instruction for use of the pharmaceutical composition to treat a subject afflicted with a progressive form of multiple sclerosis .
• This invention also provides a therapeutic package for dispensing to, or for use in dispensing to, a subject afflicted with a progressive form of multiple sclerosis, which comprises: a) one or more unit doses, each such unit dose comprising an amount of laquinimod thereof, wherein the amount of said laquinimod in said unit dose is effective, upon administration to said subject, to treat the subject, and b) a finished pharmaceutical container therefor, said container containing said unit dose or unit doses, said container further containing or comprising labeling directing the use of said package in the treatment of said subj ect .
• each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments.
• the elements recited in the pharmaceutical composition and package embodiments can be used in the method embodiments described herein and vice versa.
• Laquinimod Laquinimod mixtures, compositions, and the process for the manufacture thereof are described in, e.g., U.S. Patent No. 6,077,851, U.S. Patent No. 7,884,208, U.S. Patent No. 7,989,473, U.S. Patent No. 8,178,127, U.S. Application Publication No. 2010- 0055072, U.S. Application Publication No. 2012-0010238, and U.S. Application Publication No. 2012-0010239, each of which is hereby incorporated by reference in their entireties into this application .
• 2011- 0034508 brain-derived neurotrophic factor (BDNF) -related diseases
• U.S. Application Publication No. 2011-0218179 active lupus nephritis
• U.S. Application Publication No. 2011-0218203 rheumatoid arthritis
• U.S. Application Publication No. 2011- 0217295 active lupus arthritis
• U.S. Application Publication No. 2012-0142730 reducing fatigue, improving quality of life, and providing neuroprotection in MS patients
• a pharmaceutically acceptable salt of laquinimod as used in this application includes lithium, sodium, potassium, magnesium, calcium, manganese, copper, zinc, aluminum and iron. Salt formulations of laquinimod and the process for preparing the same are described, e.g., in U.S. Patent No. 7,589,208 and PCT International Application Publication No. WO 2005/074899, which are hereby incorporated by reference into this application.
• Laquinimod can be administered in admixture with suitable pharmaceutical diluents, extenders, excipients, or carriers (collectively referred to herein as a pharmaceutically acceptable carrier) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices.
• the unit can be in a form suitable for oral administration.
• Laquinimod can be administered alone but is generally mixed with a pharmaceutically acceptable carrier, and co-administered in the form of a tablet or capsule, liposome, or as an agglomerated powder.
• suitable solid carriers include lactose, sucrose, gelatin and agar. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders.
• Tablets may contain suitable binders, lubricants, disintegrating agents (disintegrants ) , coloring agents, flavoring agents, flow- inducing agents, and melting agents.
• the active drug component can be combined with an oral, nontoxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like.
• Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose , polyethylene glycol, waxes, and the like.
• Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like.
• Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
• Disclosed is the use of laquinimod for treating a progressive form of multiple sclerosis in a human subject.
• laquinimod means laquinimod acid or a pharmaceutically acceptable salt thereof.
• an “amount” or “dose” of laquinimod as measured in milligrams refers to the milligrams of laquinimod acid present in a preparation, regardless of the form of the preparation.
• a “dose of 0.6 mg laquinimod” means the amount of laquinimod acid in a preparation is 0.6 mg, regardless of the form of the preparation.
• the weight of the salt form necessary to provide a dose of 0.6 mg laquinimod would be greater than 0.6 mg (e.g., 0.64 mg) due to the presence of the additional salt ion.
• “about” in the context of a numerical value or range means ⁇ 10% of the numerical value or range recited or claimed.
• a "relapsing form of multiple sclerosis” means a form of multiple sclerosis characterized by relapses.
• RRMS Relapsing-Remitting MS
• PRMS Progressive Relapsing MS
• SPMS Secondary Progressive MS
• PPMS Primary Progressive MS
• a subject afflicted with a disease, disorder or condition means a subject who has been clinically diagnosed to have the disease, disorder or condition.
• a subject afflicted with PPMS means a subject who has been clinically diagnosed to have PPMS.
• PPMS can be diagnosed, e.g., as defined by the Revised McDonald Criteria (Polman 2011) .
• a "progressive form of multiple sclerosis” means a form of multiple sclerosis marked by progressive characteristics, i.e., disability progression and progressive neurologic decline. In another word, progressive forms of multiple sclerosis are marked by the absence of remissions.
• a "progressive form of multiple sclerosis” excludes Relapsing- Remitting MS (RRMS) which is characterized by clearly defined relapses followed by remissions.
• RRMS Relapsing- Remitting MS
• PRMS and SPMS have both relapsing and progressive characteristics, and thus can be both a "progressive form of multiple sclerosis” and a “relapsing form of multiple sclerosis” (see Figure 1) . Accordingly, a “progressive form of multiple sclerosis” can also be a "relapsing form of multiple sclerosis” and vice versa.
• “Expanded Disability Status Scale” or “EDSS” is a rating system that is frequently used for classifying and standardizing the condition of people with multiple sclerosis. The score ranges from 0.0 representing a normal neurological exam to 10.0 representing death due to MS. The score is based upon neurological testing and examination of functional systems (FS) , which are areas of the central nervous system which control bodily functions. The functional systems are: Pyramidal (ability to walk) , Cerebellar (coordination) , Brain stem (speech and swallowing) , Sensory (touch and pain) , Bowel and bladder functions, Visual, Mental, and Other (includes any other neurological findings due to MS) . (Kurtzke JF, 1983)
• administering to the subject means the giving of, dispensing of, or application of medicines, drugs, or remedies to a subject to relieve, cure, or reduce the symptoms associated with a disease, disorder or condition, e.g., a pathological condition.
• Treating encompasses, e.g., inducing inhibition, regression, or stasis of a disease or disorder, or lessening, suppressing, inhibiting, reducing the severity of, eliminating or substantially eliminating, or ameliorating a symptom of the disease or disorder.
• “Inhibition" of disease progression or disease complication in a subject means preventing or reducing the disease progression and/or disease complication in the subject.
• a "symptom" associated with a disease or disorder includes any clinical or laboratory manifestation associated with the disease or disorder and is not limited to what the subject can feel or observe .
• a subject at "baseline” is a subject prior to initiating periodic administration of laquinimod.
• a "naive subject” or a “naive patient” with respect to a drug or therapy means that the subject has not previously received the drug or therapy.
• a “pharmaceutically acceptable carrier” refers to a carrier or excipient that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. It can be a pharmaceutically acceptable solvent, suspending agent or vehicle, for delivering the instant compounds to the subject.
• 0.1-2.5mg/day includes 0.1 mg/day, 0.2 mg/day, 0.3 mg/day, etc. up to 2.5 mg/day.
• Progressive MS includes Primary Progressive Multiple sclerosis (PPMS) , Secondary Progressive Multiple Sclerosis (SPMS) and Progressive Relapsing MS (PRMS) .
• PPMS Primary Progressive Multiple sclerosis
• SPMS Secondary Progressive Multiple Sclerosis
• PRMS Progressive Relapsing MS
• the hallmarks of progressive forms of multiple sclerosis is progression, including EDSS disability progression (clinical) and axonal loss and damage, astrocytic and microglial activation, accompanied with neuronal loss (pathological) .
• PPMS is characterized by gradual, ongoing accrual of disability from onset. Relapses and MRI GdE-Tl activity in PPMS are relatively low compared with that in RRMS .
• SPMS is the progressive stage of multiple sclerosis experienced by ex-RRMS patients and has a more heterogeneous presentation. Conversion of RRMS to SPMS is associated with early high relapse activity, followed by steady accrual of EDSS disability between relapses. Then, relapses subside (although may occur from time to time) and EDSS disability progression continues steadily (i.e., SPMS without superimposed relapses) . SPMS is normally diagnosed retroactively .
• treatment options for SPMS patients include potent anti-inflammatory drugs (e.g., mitoxantrone , Tysabri®, Gilenya®) , IFN' s (indicated for relapsing forms of MS), as well as teriflunomide (Aubagio®) .
• potent anti-inflammatory drugs e.g., mitoxantrone , Tysabri®, Gilenya®
• IFN' s indicated for relapsing forms of MS
• teriflunomide teriflunomide
• 0.6 mg arm 0.6 mg laquinimod is administered orally once daily.
• 0.9 mg arm 0.9 mg laquinimod is administered orally once daily.
• 1.2 mg arm 1.2 mg laquinimod is administered orally once daily.
• 1.8 mg arm 1.8 mg laquinimod is administered orally once daily.
• Matching placebo for laquinimod arm matching placebo for laquinimod administered once daily.
• Subjects must be ambulatory with converted Kurtzke EDSS score of 3.0-6.5. 4. Subjects must have a Pyramidal Functional Systems (FS) score of >2. 5. Subjects must have a threshold Timed 25-Foot Walk (T25FW) score .
• FS Pyramidal Functional Systems
• Daily oral administration of 0.6 mg, 0.9 mg, 1.2 mg and 1.8 mg laquinimod reduces the accumulation of physical disability in patients afflicted with SPMS, as compared to patients in control group receiving placebo.
• Daily oral administration of 0.6 mg, 0.9 mg, 1.2 mg and 1.8 mg laquinimod reduces the accumulation of physical disability in patients afflicted with PRMS, as compared to patients in control group receiving placebo.
• Daily oral administration of 0.6 mg, 0.9 mg, 1.2 mg and 1.8 mg laquinimod reduces the accumulation of physical disability in patients afflicted with a progressive form of multiple sclerosis, as compared to the patient at baseline.
• EXAMPLE 2 Clinical Trial (Phase II) - Administration Of Laquinimod In Primary Progressive Multiple Sclerosis (PPMS) Subj ects
• Treatment Phase At least 15 months Three months after study completion, patients are offered the opportunity to enter into an extension phase in which they continue treatment with laquinimod daily.
• Subjects with Primary Progressive Multiple Sclerosis (approximately 500 subjects in approximately 120 centers, with about 125 subjects per study arm) .
• 0.6 mg arm one capsule containing 0.6 mg laquinimod and the other two containing matching placebo, to be administered orally once daily.
• 1.0 mg arm Two capsules containing 0.5 mg laquinimod and the other containing matching placebo, to be administered orally once daily.
• Placebo arm Three capsules containing placebo (0.5/0.6mg matching) to be administered orally once daily.
• ETD Early Treatment Discontinuation
• Subjects have the following study visits: Screening visit (-1 Month), Baseline visit (Month 0), and Months 1, 2, 3, 6, 9, 12, and every three months until study termination.
• CBC Complete blood count
• Serum chemistry including electrolytes, liver enzymes, urea, creatinine, glucose, total protein, albumin, direct and total bilirubin, Creatinephosphokinase (CPK) , serum conventional C- reactive protein (CRP) , fibrinogen and pancreatic amylase
• GFR Glomerular Filtration Rate
• Serum human choriogonadotropin beta ( ⁇ -hCG) in women of child-bearing potential is performed at each scheduled study visit.
• Urine ⁇ -hCG test is performed in women of child- bearing potential at baseline (month 0) and at each scheduled study visit thereafter.
• PK study Blood samples for analysis of laquinimod plasma concentrations are collected at Months 1,
• ECG is performed at months -1 (screening) , 0 (baseline, three recordings 10 min apart, before first dose), 1, 2, 3, 6, 12 and every 12 months until completion/ETD.
• Chest X-ray is performed at month -1, (if not performed within 6 months prior to the screening visit) .
• study MRI is performed before such treatment or delayed to allow a minimum of 14 days but not more than 28 days from the completion of the steroid course .
• All subjects - MRI including 3D Tl-w acquisitions of the brain and cervical cord, to measure whole brain volume, cord atrophy, thalamic atrophy, cortical atrophy and white matter (WM) atrophy at Months 0 (Baseline) , 12 or ETD (if applicable) .
• 3D Tl-w acquisitions of the brain and cervical cord to measure whole brain volume, cord atrophy, thalamic atrophy, cortical atrophy and white matter (WM) atrophy at Months 0 (Baseline) , 12 or ETD (if applicable) .
• Neurological evaluations including Expanded Disability Status Scale (EDSS) , Timed 25-Foot Walk (T25FW) / 9- Hole Peg test (9HPG), Ambulation Index (AI), Functional systems (FS), are performed at months -1 ,0, and every 3 months thereafter, ETD visit (if applicable) and until completion visit .
• EDSS Expanded Disability Status Scale
• T25FW Timed 25-Foot Walk
• 9HPG 9- Hole Peg test
• AI Ambulation Index
• FS Functional systems
• BICAMS The Brief International Cognitive Assessment for MS (BICAMS) , including SDMT, is evaluated at months 0 and every 12 months until completion/ETD.
• LCVA Low contrast visual acuity
• the general health status is assessed by the EuroQoL (EQ5D) questionnaire at month 0 and every 12 months until completion/ETD .
• the allowed treatment for a relapse is intravenous methylprednisolone lgr/day for up to 5 consecutive days.
• CSF assessment- CSF is collected from all subjects at month 0 (baseline), and month 12.
• PGx Pharmacogenomic
• DNA and RNA Blood samples for PGx analysis (DNA and RNA) are collected at Baseline (or if not possible at the next possible visit) from all subjects.
• the objective of this study is to collect and store DNA and RNA samples for possible association analysis of genetic polymorphisms, and/or gene expression profiles with clinical or paraclinical (MRI) treatment responses to laquinimod doses, in comparison with placebo.
• MRI clinical or paraclinical
• Magnetization Transfer (selected sites) is assessed in all subjects at Months 0 (Baseline), 12, and ETD (if applicable) .
• OCT optical coherence tomography
• Subject must have a confirmed and documented PPMS diagnosis as defined by the Revised McDonald criteria (Polman 2011) .
• Subject must have lesions consistent with PPMS in either or both brain MRI and cervical spinal cord MRI. 3. Subject must have Kurtzke EDSS score of 3-6.5, inclusive, at both screening and randomization visits.
• Subject must have evidence of clinical disability progression (retrospectively or prospectively determined) whithin two years prior to randomization.
• Subject must have Function System scale score of >2 for the pyramidal system or gait impairment due to lower extremity dysfunction .
• Subject must be between 25 to 55 years of age, inclusive.
• Subject must be able to sign and date a written informed consent prior to entering the study.
• Women of child-bearing potential must practice an acceptable method of birth control until 30 days after the last dose of treatment was administered [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, barrier methods (condom or diaphragm with spermicide) .
• Hormonal methods of birth control e.g. oral contraceptive, contraceptive patch, long-acting injectable contraceptive are permitted but must be accompanied by a condom or a diaphragm] .
• immunosuppressive agents or cytotoxic agents, including cyclophosphamide and azatioprine within 12 months prior to Baseline.
• mitoxantrone within 5 years prior to Screening.
• Use of mitoxantrone (Novantrone) >5 years before screening is allowed in subjects with normal ejection fraction and who did not exceed the total lifetime maximal dose .
• Serum levels ⁇ 3xULN of either ALT or AST at screening Serum levels ⁇ 3xULN of either ALT or AST at screening.
• Serum direct bilirubin which is ⁇ 2xULN at screening.
• Such conditions may include:
• a major cardiovascular event e.g. myocardial infarction, acute coronary syndrome, de-compensated congestive heart failure, pulmonary embolism, coronary revascularization
• a major cardiovascular event e.g. myocardial infarction, acute coronary syndrome, de-compensated congestive heart failure, pulmonary embolism, coronary revascularization
• Brain atrophy as defined by the percentage change in brain volume from Baseline to month 12. For subjects that performed ETD, the last MRI scan is included in the analysis if performed at least 9 months under study.
• CDP disease progression
• CDP Time to confirmed disease progression
• Advanced MRI thalamic atrophy, cortical and WM atrophy

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Epidemiology (AREA)
• Psychiatry (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Quinoline Compounds (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (13)

Applications Claiming Priority (4)

Publications (1)

Family

ID=51351655

Family Applications (1)

Country Status (18)

Cited By (2)

Families Citing this family (7)

Citations (4)

Family Cites Families (8)

• 2014
  • 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
  • 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
  • 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
  • 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
  • 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
  • 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
  • 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
  • 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
  • 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
  • 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
  • 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
  • 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
  • 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
  • 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
  • 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
  • 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
  • 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
• 2015
  • 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
  • 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
• 2017
  • 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events